Effectiveness and Safety of New Dose of Copaxone® Compared to the Currently Approved Dose

Study Title

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxoneֲ® Compared to Copaxoneֲ® 20mg, the Currently Approved Dose

Teva Identifier

9006

ClinicalTrials.gov Identifier

NCT00202982

Study Status

Completed

Trial Condition(s)

Relapse-Remitting Multiple Sclerosis

Interventions

Drug: glatiramer acetate 20 mg | Drug: glatiramer acetate 40 mg

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 50 Years

Trial Duration

08/01/2003 - 09/01/2005

Phase

Phase 2

Study Type

Interventional